It’s oddly appropriate that a poison pill could settle the saga of two pharmaceutical firms. Will a stichting in time save Mylan NV? Or will the generic drugmaker’s move to stave off a $40 billion hostile takeover by Teva Pharmaceutical Industries Ltd. trigger a legal battle in a Netherlands court?
It comes down to how badly Jerusalem-based Teva (NYSE:TEVA) wants to buy Mylan (Nasdaq:MYL), whose executive team is based in Southpointe but was incorporated in the Netherlands early in 2015 via…
Walang komento:
Mag-post ng isang Komento